The Veterinary Vaccines Market size in 2026 plays an important role in protecting companion animals and livestock against infectious diseases. Veterinary vaccines stimulate protective immune responses, helping animals develop resistance to specific pathogens and reducing the risk of serious disease outbreaks. These products support animal welfare, livestock productivity, and preventive veterinary healthcare while helping address infections that can spread between animals and humans.

According to Fortune Business Insights, the global veterinary vaccines market size was valued at USD 12.51 billion in 2025. The market is projected to grow from USD 13.05 billion in 2026 to USD 21.86 billion by 2034, exhibiting a CAGR of 6.66% during the forecast period. North America dominated the veterinary vaccines market with a market share of 45.42% in 2025.

Demand for veterinary immunization is supported by increasing pet ownership, awareness of animal health, livestock production requirements, and efforts to manage zoonotic diseases. Vaccine manufacturers are also investing in research and development to introduce new formulations and improve disease prevention across different animal categories. These developments are strengthening the role of vaccination in modern animal healthcare.

Top Companies In The Market

  • Elanco (U.S.)
  • HIPRA (Spain)
  • Boehringer Ingelheim International GmbH (Germany)
  • Virbac (France)
  • Merck Animal Health (U.S.)
  • Zoetis Services LLC (U.S.)
  • Ceva (France)
  • NEOGEN CORPORATION (U.S.)
  • Hester Biosciences Limited (India)

Market Drivers & Restraints:

Growing Awareness of Preventive Animal Healthcare: Greater awareness of vaccination and routine veterinary care is supporting demand for animal vaccines. Pet owners are increasingly seeking preventive healthcare, while livestock producers use vaccination programs to reduce disease-related losses and maintain animal health. These practices are creating opportunities for manufacturers across companion and livestock vaccine categories.

Increasing Focus on Zoonotic Diseases: Infectious diseases affecting animals can threaten livestock productivity and, in some cases, public health. Efforts to control transmissible diseases are encouraging vaccination programs and research into new preventive solutions. Government-led immunization campaigns are also supporting demand for effective veterinary vaccines.

Research and Product Innovation: Manufacturers are developing new vaccine formulations and technologies to improve protection against animal diseases. Recombinant DNA and mRNA-based research are contributing to the development of innovative approaches to veterinary immunization. In February 2025, Boehringer Ingelheim launched its VAXXITEK HVT+IBD+H5 trivalent vaccine for poultry to protect against Marek’s disease, infectious bursal disease, and H5 avian influenza.

Limited Access to Vaccination: In developing regions, limited veterinary infrastructure, low awareness, and economic constraints can restrict vaccine access. Insufficient investment in veterinary services and education can also affect immunization coverage among livestock and companion animals.

Market Segments:

By Product (Inactivated, Live Attenuated, Recombinant, and Others)

By Animal (Companion {Feline, Canine, Avian, and Others}, and Livestock {Poultry, Porcine, Bovine, and Others})

By Route of Administration (Oral, Parenteral, and Others)

By Distribution Channel (Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores, and Others)

Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/industry-reports/veterinary-animal-vaccines-market-101532

Market Regional Insights:

North America dominated the market in 2025, reaching USD 5.68 billion and accounting for 45.42% of global demand. The regional market is projected to reach USD 5.93 billion in 2026. Advanced veterinary healthcare facilities, pet ownership, immunization adoption, and new product introductions support regional growth. The U.S. market is projected to reach USD 5.25 billion in 2026.

Europe generated USD 3.26 billion in 2025, representing 26.03% of the global market, and is projected to reach USD 3.39 billion in 2026. Increasing pet ownership, concerns about zoonotic diseases, veterinary services, and established animal health companies support demand.

Asia Pacific reached USD 1.81 billion in 2025, accounting for 14.45% of the market, and is projected to reach USD 1.89 billion in 2026. Growing awareness of preventive animal healthcare and government initiatives to improve vaccine access are supporting the region. China is projected to reach USD 0.76 billion in 2026, while Japan is expected to reach USD 0.51 billion.

Future Market Scope:

The future of the veterinary vaccines market will be influenced by preventive animal healthcare, livestock disease management, companion animal vaccination, and advances in vaccine technology. Recombinant and mRNA research may create opportunities for developing new immunization approaches, while government vaccination programs can improve access in underserved markets. Manufacturers are expected to continue investing in research, product launches, and distribution networks to address evolving animal health needs. Improved vaccination coverage and continued innovation are expected to support the market’s long-term development.

What’s Driving Japan’s Market? Discover the Latest -Veterinary/Animal Vaccines Market- Insights